Clinical usefulness of a long-term treatment with an antithyroid drug for psoriasis vulgaris

Journal of Dermatology

Volumn 31, Issue 10, 2004, Pages 794-797

  Hasegawa, Michiko ^a   Abe, Masatoshi ^a   Ohnishi, Kazunori ^a   Shoji, Chizuru ^a   Ishikawa, Osamu ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antithyroid thiourethylenes; Psoriasis vulgaris; Thiamazole

Indexed keywords

ANTITHYROID AGENT; CHLORCYCLIZINE; LIOTHYRONINE; STEROID; TACALCITOL; THIAMAZOLE; THIOURETHYLENE DERIVATIVE; THYROTROPIN; THYROXINE; UNCLASSIFIED DRUG;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LIOTHYRONINE BLOOD LEVEL; LIVER TOXICITY; LONG TERM CARE; MALE; PRURITUS; PSORIASIS VULGARIS; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL;

EID: 7944232883     PISSN: 03852407     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2004.tb00601.x     Document Type: Article

References (13)

1. Bartalena L, Bogazzi F, Martino E: Adverse effects of thyroid hormone preparations and antithyroid drugs, Drug-Saf, 15: 53-63, 1996.
2. Elias AN, Goodman MM, Rohan MK, et al: Methimazole (2-mercapto 1-methyllmidazole) in psoriasis-Results of an open trial, Dermatology, 187: 26-29, 1993.
3. Elias AN, Goodman MM, Liem WH, et al: Propylthiouracil in psoriasis: Results of an open trial, J Am Acad Dermatol, 29: 78-81, 1993.
4. Abe M, Ohnishi K, Aoyama K, et al: The clinical usefulness of psoriasis vulgaris treatment with an antithyroid drug by the Gunma University method, Jpn J Dermatol, 110: 1549-1556, 2000. (in Japanese)
5. Elias AN, Barr RJ: Low-dose oral propylthiouracil in the treatment of plaque psoriasis, Int J Dermatol, 34: 519-520, 1995.
6. Elias AN, Barr RJ, Rohan MK, et al: Effect of orally administered antithyroid thioureylenes on PCNA and P53 expression in psoriatic lesions, Int J Dermatol, 34: 280-283, 1995.
7. Elias AN, Goodman MM, Rohan MK: Effect of propylthiouracil and methimazole on serum levels of intreleukin-2 receptors in patients with psoriasis, Int J Dermatol, 32: 537-540, 1993.
8. Elias AN, Goodman MM, Rohan MK: Serum ICAM-1 concentrations in patients with psoriasis treated with antithyroid thioureylenes, Clin Exp Dermatol, 18: 526-529, 1993.
9. Weetman AP: Effect of antithyroid drug methimazole on interleukin-1 and interleukin-2 levels in vitro, Clin Endomnol, 25: 133-142, 1986.
10. Tötterman TH, Karlsson FA, Bengtsson M, et al: Induction of circulating activated suppressor-like T cells by methimazole therapy for Graves' disease, N Eng J Med, 316: 15-22, 1987.
11. Ohashi H, Okugawa T, Itoh M: Circulating activated T cell subsets in autoimmune thyroid disease; differences between untreated and treated patients, Acta Endomnol, 125: 502-509, 1991.
12. Raychaudhuri SP, Farber EM, Raychaudhuri SK: Immunomodulatory effects of peptide T on Th 1/Th 2 cytokines, Int J Immunopharmacol, 21: 609-615, 1999.
13. Abe M, Ohnishi K, Hasegawa M, et al: The antipsoriatic effect of thiamazole is not accompanied either by significant changes in blood lymphocyte subsets nor by serum concentration of TNF-alpha, Eur J Dermatol, 12: 335-339, 2002.